FDA Publicly Shares Drug Rejection Letters

The FDA recently announced a change. It will now publicly share more letters about rejected drugs. This means people can see why the FDA did not approve certain medicines.

This policy started in late 2023. It aims to make drug approvals more open. However, some groups had concerns. The FDA paused the policy in April to address these worries.

Now the pause is over. The FDA believes being open helps everyone. It lets the public and drug makers understand decisions better. This helps build trust in the approval process.

Source: FierceBiotech